TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

Date publication

février 2016

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier , Dr LIMACHER Jean-Marc , Pr WESTEEL Virginie

Tous les auteurs :
Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26727163

Résumé

MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2. In a previous study, TG4010 combined with chemotherapy showed activity in non-small-cell lung cancer and the baseline value of CD16, CD56, CD69 triple-positive activated lymphocytes (TrPAL) was shown to be potentially predictive of TG4010 efficacy. In this phase 2b part of the phase 2b/3 TIME trial, we further assess TG4010 in combination with first-line chemotherapy and use of the TrPAL biomarker in this setting.

Mots clés

Aged, Anemia, etiology, Antigens, CD, analysis, Antigens, CD56, analysis, Antigens, Differentiation, T-Lymphocyte, analysis, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bevacizumab, administration & dosage, Biomarkers, Tumor, blood, Cancer Vaccines, adverse effects, Carboplatin, administration & dosage, Carcinoma, Non-Small-Cell Lung, chemistry, Cisplatin, administration & dosage, Deoxycytidine, administration & dosage, Disease-Free Survival, Double-Blind Method, Erlotinib Hydrochloride, administration & dosage, Fatigue, etiology, Female, Humans, Immunotherapy, adverse effects, Lectins, C-Type, analysis, Lung Neoplasms, chemistry, Lymphocyte Activation, Lymphocytes, chemistry, Male, Membrane Glycoproteins, adverse effects, Middle Aged, Mucin-1, analysis, Neutropenia, etiology, Paclitaxel, administration & dosage, Pemetrexed, administration & dosage, Predictive Value of Tests, Receptors, IgG, analysis

Référence

Lancet Oncol.. 2016 Feb;17(2):212-23